不同糖耐量人群及糖尿病患者血浆内脂素与血糖及胰岛功能的关系研究

目的探讨不同糖耐量人群血浆内脂素的变化及其与体重指数(BMI)、腰围、血糖、胰岛素抵抗指数、胰岛B细胞功能、血脂等的关系。方法2006年4月至2006年10月在南京医科大学第一附属医院门诊常规健康体检及糖尿病初次就诊者95名,按WHO1999糖尿病诊断标准分为初诊2型糖尿病组(53例)、糖耐量减退组(7例)、正常糖耐量组(35名);以WHO1998肥胖诊断标准分为超重或肥胖组(50名)、正常体重组(45名)。检测受试者BMI、腰围、血压,测定空腹血浆内脂素、血糖、血脂、胰岛素等。结果初诊2型糖尿病患者空腹血浆内脂素明显高于正常糖耐量组(P<0.01)。超重或肥胖组与正常体重组间血浆内脂素差异无显著性意义。人群中血浆内脂素与空腹血糖(r=0.338,P<0.01)、餐后2h血糖(r=0.340,P<0.01)、胰岛素抵抗指数(r=0.227,P<0.05)呈正相关,与胰岛素分泌指数(HOMA-B)呈负相关(r=-0.296,P<0.05)。在2型糖尿病组,血浆内脂素与糖化血红蛋白(HbA1c)呈正相关(r=0.356,P<0.01)。多元线性逐步回归分析表明,餐后2h血糖是影响血浆内脂素的独立相关因素。结论初诊2型糖尿病患者血浆内脂素显著升高,可能是机体针对体内血糖增高、胰岛功能受损所发生的一种代偿效应。     

多囊卵巢综合征患者超长链脂肪酸的变化及其与肥胖、胰岛素抵抗的关系

目的 了解多囊卵巢综合征（PCOS）患者血浆超长链脂肪酸（VLCFAs）的变化,并分析各种脂肪酸与肥胖、胰岛素抵抗的关系.方法 收集符合2003年鹿特丹会议诊断标准的18 ～40岁PCOS患者205例,另选择年龄匹配的同期因输卵管因素或男方因素所致不孕的女性117例作为正常对照组.检测血清激素水平,并用气相色谱质谱联用仪（GC-MS）检测血浆10种VLCFAs水平.两组间比较采用f检验,计量资料的多因素分析采用多元逐步回归分析.结果 与正常对照组相比,PCOS患者血浆中存在多种超长链脂肪酸代谢紊乱,包括花生四烯酸（C20：4n-6）/二十碳三烯酸（C20：3n-6）较正常对照组降低,而花生烯酸（C20：ln-9）、二十碳五烯酸（C20：5n-3）、w-3二十二碳五烯酸（C22：5n-3）、二十二碳六烯酸（C22：6n-3）、C20：3n-6、二十二碳四烯酸（C22：4n-6）、二十碳二烯酸（C20：2n-7）均较正常对照组升高（t=0.539 ～6.155,均P＜0.05）.在PCOS患者中,与非肥胖组相比,肥胖组C20：0升高,C20：3n-6、C20：2n-7均下降（t=-0.927、2.452、0.767,均P＜0.05）.与非胰岛素抵抗（IR）组比较,IR组C20：0升高,C20：2n-7及C22：5n-3均降低（t=2.064、2.195、2.183,均P＜0.05）.多元逐步回归分析结果显示C20：2n-7是肥胖的独立危险因素,而C20：0是胰岛素抵抗的独立危险因素.结论 PCOS患者存在超长链脂肪酸代谢紊乱.C20：2n-7的下降可能是PCOS患者肥胖的影响因素,而C20：0的升高则可能是PCOS患者胰岛素抵抗的影响因素.     

多囊卵巢综合征患者代谢综合征患病风险研究

目的 研究多囊卵巢综合征(PCOS)患者代谢综合征(MS)患病率,并探讨MS发生的危险因素.方法 比较348例年轻的PCOS患者及113名非PCOS正常女性的MS及其组分的患病率.结果 PCOS组MS的患病率为27.0%,明显高于正常对照组的10.6%(P<0.01),除甘油三酯外,其他MS组分在PCOS组均高于正常对照组(P<0.05或P<0.01),但校正年龄和体重指数(BMI)后,差异就不存在统计学意义(P=0.737).分层分析也显示PCOS非肥胖组和肥胖组的MS患病率与相应的正常对照组均无明显差异(均P>0.05).多元逐步回归分析显示稳态模型评估的胰岛素抵抗指数(HOMA-IR)和BMI是MS的独立预测因素(均P<0.01).结论 肥胖和胰岛素抵抗是MS的独立危险因素,PCOS单独并不增加MS的发生风险.     

多囊卵巢综合征患者肥胖和高雄激素血症与胰岛素抵抗的相关性

收集多囊卵巢综合征(PCOS)患者101例,招募30名正常健康志愿者。根据血清雄激素水平及稳态模型评估的胰岛素抵抗指数(HOMA-IR)水平分层分析肥胖、高雄激素和胰岛素抵抗的关系。结果显示,101例PCOS患者中39.8％患者体重正常,24.5％超重,35.7％肥胖。将PCOS患者分为正常雄激素组(睾酮＜0.51 μg/L)和高雄激素组(睾酮≥0.51 μg/L),两组体重指数(BMI)、空腹血糖(FPG)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及HOMA-IR均无统计学差异。将PCOS患者分为非胰岛素抵抗组(HOMA-IR＜2.29)和胰岛素抵抗组(HOMA-IR≥2.29),两组血清睾酮水平无统计学差异,胰岛素抵抗组的BMI、FPG、TG、TC、LDL-C明显高于非胰岛素抵抗组(P＜0.05或P＜0.01),HDL-C明显低于非胰岛素抵抗组(P＜0.01)。HOMA-IR与BMI显著相关(P＜0.01),而与血清睾酮水平无显著相关性,提示PCOS患者体重增加与HOMA-IR的相关性独立于血清睾酮水平。     

Elevated fasting insulin is associated with cardiovascular and metabolic risk in women with polycystic ovary syndrome

AimsPCOS is associated with various immediate and long term health complications. The aim of this study was to investigate the association of serum fasting insulin concentration with cardiovascular and metabolic risk factors in women with polycystic ovary syndrome.MethodsA total of 349 women, 249 women with polycystic ovary syndrome and 100 age-matched healthy controls, were recruited in this case-control study. Fasting insulin and various other biochemical, hormonal and clinical parameters were measured in all participants. The correlation of insulin with cardiometabolic risk factors was evaluated in PCOS women with normal and high serum insulin concentration.ResultsFasting Insulin, BMI, WHR, FAI, LH: FSH, HOMA, QUICKI were significantly higher in PCOS women compared with healthy controls (p < 0.01). Fasting insulin showed a positive correlation with more cardiovascular and metabolic risk factors in PCOS compared to controls. The BMI, BAI, LAP, HOMA IR, QUICKI and FAI were significantly higher (all p < 0.05) in PCOS patients with higher insulin levels than with PCOS women with normal levels.ConclusionFasting insulin is an important determinant in the pathogenesis of obesity and hyperandrogenism in PCOS. It is associated with an increased risk of cardiovascular and metabolic disorders in women with PCOS.     

不同血糖状态人群血浆内脂素水平及其相关因素

空腹血浆内脂素水平在正常糖耐量、糖耐量受损或空腹血糖受损、2型糖尿病组分别为[(17.64±1.37,27.423±1.34和26.55±1.64)μg/L,P<0.05],但与肥胖无关.血浆内脂素水平与HbA1c呈正相关(r=0.317,P<0.01).多元线性逐步回归分析表明HbA1c、空腹血糖是影响血浆内脂素的独立相关因素.提示血浆内脂素水平与糖代谢状态有关,可能在2型糖尿病的发生、发展中具有一定的作用.     

不同胰岛素抵抗状态下多囊卵巢综合征患者内分泌指标与卵巢超声特征的相关性研究

目的 探讨伴或不伴IR的多囊卵巢综合征(PCOS)患者内分泌指标与超声特征的相关性.方法 将195例PCOS患者分为IR(PCOS-IR)组和非IR(PCOS-NIR)组,另选健康对照(NC)组50名.检测各组FIns、睾酮(T)、黄体生成素(LH)、卵泡刺激素(FSH)、卵巢体积(OV)、卵泡最大直径等指标.结果 PCOS-IR组BMI[(22.73±2.35)vs(20.97±2.33)kg/m2,P＜0.01]、FIns[(39.22±28.30)vs (6.13±3.59)μU/ml,P＜0.01]、胰岛素抵抗指数(HOMA-IR)[(8.40±7.15)vs(1.26±0.75),P＜0.01]、T[(0.74±0.21) vs (0.53±0.11) ng/ml,P＜0.01]和OV[(12.76±3.78)vs(11.43±4.01)ml,P＜0.05]大于PCOS-NIR组,卵泡最大直径[(5.08±1.63)vs(7.05±1.72)mm,P＜0.01]小于PCOS-NIR组.PCOS患者OV与BMI、HOMA-IR、T、LH/FSH呈正相关,卵泡最大直径与BMI、HOMA-IR、T呈负相关. 结论 PCOS合并IR患者OV增大,卵泡最大直径减小.OV与IR、高雄激素血症呈正相关,卵泡大小与其呈负相关.IR影响卵巢形态.     

Vascular compliance in women with polycystic ovary syndrome treated with spironolactone

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age in the United States and has been associated with several diseases including cardiovascular disease, obesity, and glucose intolerance. In this study, systolic blood pressure, diastolic blood pressure, pulse pressure (vascular compliance), large artery elasticity, systemic vascular resistance (SVR), total vascular impedance (TVI), and body mass index (BMI) were measured before and after treatment with spironolactone in 10 women with PCOS. Systolic BP, diastolic BP, and BMI were similar prior to treatment and after treatment. Pulse pressure decreased slightly post‐treatment compared to pretreatment but not to significance (P = 0.07). The results show that after treatment with spironolactone, there was a statistically significant increase in large artery elasticity (P = 0.047), while there was a statistically significant decrease in SVR and TVI (P = 0.0005 and P = 0.03). This study indicates that treatment with spironolactone improves large artery elasticity and reduces systemic vascular resistance without any change in small artery elasticity.     

多囊卵巢综合征患者血清apelin蛋白水平及意义

目的 检测多囊卵巢综合征(PCOS)患者血清apelin蛋白水平并探讨其变化意义.方法 50名PCOS患者及20名健康对照者的空腹血糖、胰岛素、胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白水平应用化学发光法检测,卵泡刺激素、黄体生成素、雌二醇,孕酮、催乳素、睾酮的血清浓度采取磁酶免疫法测定,血清apelin水平采用酶联免疫法测定.结果 PCOS组apelin血清浓度明显高于对照组(P＜0.05);其中PCOS体重指数(BMI)≥25 kg/m2患者血清apelin水平高于PCOS BMI ＜25 kg/m2患者(P＜0.05);PCOS患者血清apelin水平与胰岛素抵抗(IR)、BMI、腰臀比(WHR)呈正相关(r=0.43,P ＜0.007;r =0.38,P ＜0.02;r =0.456,P ＜0.003),与高密度脂蛋白(HDL,r=-0.456,P＜0.005)呈负相关;二项Logistic回归分析显示apelin与PCOS发病有关(P＜0.05).结论 PCOS患者血清apelin水平升高,可能参与胰岛素代谢及血管舒缩.     

饮食疗法对多囊卵巢综合征患者人体测量学和胰岛素敏感性的影响

目的 探讨饮食干预对多囊卵巢综合征患者体质量及胰岛素敏感性的影响.方法 2009年6月至2010年2月在复旦大学附属妇产科医院内分泌专科门诊入选31例多囊卵巢综合征患者(年龄19 ～30岁),根据体质指数将其分至肥胖多囊卵巢综合征组(n=17,体质指数≥25 kg/m2)和非肥胖多囊卵巢综合征组(n=14,体质指数＜2...     

Comparison of body mass index and metabolic parameters with serum vaspin levels in women with polycystic ovary syndrome

This study showed that there is a positive correlation between serum Visceral Adipose tissue derived Serine Protease Inhibitor (VASPIN) level and polycystic ovary syndrome (PCOS). In previous studies, this relation was attributed to the generalization of higher amount of adipose tissue in patients with PCOS. However, we detected that VASPIN is significantly high in patients with PCOS regardless of BMI. Besides, the metabolic parameters such as fasting insulin, HOMA-IR, triglycerides and LDL-C levels were also increased in lean women with PCOS.     

Adiponectin levels in women with polycystic ovary syndrome

Serum adiponectin levels were evaluated in 60 women with polycystic ovary syndrome (PCOS), 30 normal-weighted and 30 obese women, and 60 healthy women age and body mass index (BMI) matched with the patients. The homeostasis model assessment (HOMA) score was also calculated. Both in PCOS and controls, serum adiponectin levels were significantly (P < 0.05) lower in obese than normal-weight women, without any difference between PCOS and controls. The HOMA score was significantly (P < 0.05) higher in obese than normal-weight women both in PCOS and controls; additionally, the HOMA score was significantly (P < 0.05) higher in normal-weight PCOS than normal-weight controls. Both in PCOS and controls, adiponectin levels were significantly correlated with BMI (r = -0.51, P < 0.01 in PCOS; r = -0.45, P < 0.01 in controls) and HOMA values (r = -0.39, P < 0.05 in PCOS; r = -0.35, P < 0.05 in controls); HOMA was correlated with BMI (r = 0.51, P < 0.01 in PCOS, r = 0.61, P < 0.001 in controls). In conclusion, our results confirm that adiponectin concentrations change according to variations of fat mass. They further suggest that insulin sensitivity per se probably does not play any pivotal role in the control of adiponectin levels in PCOS women.     

多囊卵巢综合征的药物治疗

多囊卵巢综合征是一种涉及多系统的内分泌疾病,常伴有代谢紊乱和心血管疾患.传统的治疗药物包括口服避孕药、促排卵药、抗雄激素药等,新的治疗药物包括双胍类、噻唑烷二酮类、他汀类、芳香化酶抑制剂等.本文就多囊卵巢综合征药物治疗的研究进展作一综述.     

Nonalcoholic fatty liver disease and polycystic ovary syndrome

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world comprising a spectrum of liver damage from fatty liver infiltration to end-stage liver disease, in patients without significant alcohol consumption. Increased prevalence of NAFLD has been reported in patients with polycystic ovary syndrome (PCOS), one of the most common endocrinopathies in premenopausal women, which has been redefined as a reproductive and metabolic disorder after the recognition of the important role of insulin resistance in the pathophysiology of the syndrome. Obesity, in particular central adiposity and insulin resistance are considered as the main factors related to NAFLD in PCOS. Moreover, existing data support that androgen excess, which is the main feature of PCOS and is interrelated to insulin resistance, may be an additional contributing factor to the development of NAFLD. Although the natural history of NAFLD remains unclear and hepatic steatosis seems to be a relatively benign condition in most patients, limited data imply that advanced stage of liver disease is possibly more frequent in obese PCOS patients with NAFLD. PCOS patients, particularly obese patients with features of the metabolic syndrome, should be submitted to screening for NAFLD comprising assessment of serum aminotransferase levels and of hepatic steatosis by abdominal ultrasound. Lifestyle modifications including diet, weight loss and exercise are the most appropriate initial therapeutic interventions for PCOS patients with NAFLD. When pharmacologic therapy is considered, metformin may be used, although currently there is no medical therapy of proven benefit for NAFLD. Long-term follow up studies are needed to clarify clinical implications and guide appropriate diagnostic evaluation, follow-up protocol and optimal treatment for PCOS patients with NAFLD.     

多囊卵巢综合征患者血清瘦素水平测定的意义

为了探讨多囊卵巢综合征(PCOS)患者血清瘦素(Leptin)水平测定的临床意义,选择47例PCOS患者与34例体重相匹配的对照妇女,于卵泡期测定Leptin、体重指数(BMI)、腰围(WC)、腰臀比(WHR)、胰岛素(INS)、内分泌激素,并对其进行相关与回归分析。结果:PCOS组血清Leptin浓度(18.69±8.05)ng/ml,对照组(17.09±10.35)ng/ml,差异无显著性(P>0.05);PCOS组血清INS浓度(12.45±8.07)mU/L,对照组(5.95±1.19)mU/L,差异有显著性(P<0.01)。Leptin与BMI、WC、WHR、INS成正相关。认为PCOS患者血清Leptin水平并不高于对照组,Leptin水平与体脂分布、INS有关,可能间接参与PCOS的病变形成。     

内脂素研究进展

内脂素是一种主要由内脏脂肪分泌的细胞因子,通过与胰岛素受体结合发挥类胰岛素样的降血糖作用,并促进脂肪组织的分化与合成。有研究认为内脂素由于结构缺陷可能并非真正具类胰岛素样作用。尽管如此,内脂素仍为肥胖和糖尿病治疗提供可能靶点。     

多囊卵巢综合征胰岛素抵抗的发生机制

多囊卵巢综合征（PCOS）是一种发病多因性、临床表现多态性的综合征，以慢性持续的无排卵和高雄激素血症为基本病理生理改变。研究证实胰岛素抵抗（IR）可能是PCOS发生发展的主要因素之一，本文就PCOS-IR发生机制的研究进展作一综述。